PL2470671T3 - Przeciwciała antykinowe wiążące się z wieloma chemokinami CC - Google Patents

Przeciwciała antykinowe wiążące się z wieloma chemokinami CC

Info

Publication number
PL2470671T3
PL2470671T3 PL10812667T PL10812667T PL2470671T3 PL 2470671 T3 PL2470671 T3 PL 2470671T3 PL 10812667 T PL10812667 T PL 10812667T PL 10812667 T PL10812667 T PL 10812667T PL 2470671 T3 PL2470671 T3 PL 2470671T3
Authority
PL
Poland
Prior art keywords
chemokines
bind
antikine antibodies
antikine
antibodies
Prior art date
Application number
PL10812667T
Other languages
English (en)
Inventor
Dan Allison
Carol Raport
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PL2470671T3 publication Critical patent/PL2470671T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL10812667T 2009-08-28 2010-08-27 Przeciwciała antykinowe wiążące się z wieloma chemokinami CC PL2470671T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23801509P 2009-08-28 2009-08-28
EP20100812667 EP2470671B1 (en) 2009-08-28 2010-08-27 Antikine antibodies that bind to multiple cc chemokines
PCT/US2010/047004 WO2011025962A1 (en) 2009-08-28 2010-08-27 Antikine antibodies that bind to multiple cc chemokines

Publications (1)

Publication Number Publication Date
PL2470671T3 true PL2470671T3 (pl) 2015-05-29

Family

ID=43628404

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10812667T PL2470671T3 (pl) 2009-08-28 2010-08-27 Przeciwciała antykinowe wiążące się z wieloma chemokinami CC

Country Status (18)

Country Link
US (3) US8313747B2 (pl)
EP (1) EP2470671B1 (pl)
JP (2) JP6109571B2 (pl)
KR (1) KR101778813B1 (pl)
CN (1) CN102782148B (pl)
AU (1) AU2010286516B2 (pl)
BR (1) BR112012004387A2 (pl)
CA (1) CA2771781C (pl)
DK (1) DK2470671T3 (pl)
ES (1) ES2531561T3 (pl)
HR (1) HRP20150162T1 (pl)
IN (1) IN2012DN01769A (pl)
MX (1) MX2012002427A (pl)
PL (1) PL2470671T3 (pl)
PT (1) PT2470671E (pl)
SI (1) SI2470671T1 (pl)
SM (1) SMT201500011B (pl)
WO (1) WO2011025962A1 (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2531561T3 (es) * 2009-08-28 2015-03-17 Regeneron Pharmaceuticals, Inc. Anticuerpos de antiquina que se enlazan a múltiples quimioquinas CC
EP2717941B1 (en) * 2011-06-13 2020-04-01 TLA Targeted Immunotherapies AB Treating cancer
WO2013033206A2 (en) * 2011-08-29 2013-03-07 University Of Rochester Compositions and methods for inhibiting ccl3
WO2013036290A1 (en) * 2011-09-09 2013-03-14 Yale University Compositions and methods for assessing and treating inflammatory diseases and disorders
EP2888283B1 (en) 2012-08-24 2018-09-19 The Regents of The University of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
TWI612059B (zh) * 2013-03-15 2018-01-21 美國禮來大藥廠 泛－ＥＬＲ<sup>＋</sup>ＣＸＣ趨化因子抗體
AU2014268316B2 (en) 2013-05-23 2019-10-10 Takeda Pharmaceutical Company Limited Anti-CCL2 and anti-LOXL2 combination therapy for treatment of scleroderma
JP6220222B2 (ja) * 2013-10-28 2017-10-25 シスメックス株式会社 関節リウマチの診断を補助するための方法、システム及びコンピュータプログラム製品
JP6549143B2 (ja) * 2013-12-09 2019-07-24 アラコス インコーポレイテッド 抗シグレック−８抗体およびその使用の方法
US10183996B2 (en) 2014-02-28 2019-01-22 Allakos Inc. Methods and compositions for treating Siglec-8 associated diseases
ES2926700T3 (es) * 2014-03-04 2022-10-27 Chemomab Ltd Anticuerpos anti Eotaxina-2 que reconocen quimiocinas de unión a CCR3 adicionales
CN104198727A (zh) * 2014-08-22 2014-12-10 广西南宁隆吉维特生物科技有限公司 人血清ccl2酶联免疫检测试剂盒及其制备和使用方法
TWI566780B (zh) * 2014-10-24 2017-01-21 國立陽明大學 巨噬細胞發炎蛋白－１β（ＭＩＰ－１β）抑制劑用於促進血管新生以改善組織缺血及糖尿病血管病變的用途
SI3808775T1 (sl) * 2014-12-09 2024-08-30 Regeneron Pharmaceuticals, Inc. Nehumane živali s humaniziranim genom označevalca pripadnosti 274
JP6846362B2 (ja) 2015-06-17 2021-03-24 アラコス インコーポレイテッド 線維性疾患を処置するための方法および組成物
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
WO2018005519A2 (en) 2016-06-27 2018-01-04 The Regents Of The University Of California Cancer treatment combinations
EP3551046B1 (en) 2016-12-07 2023-07-19 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
JP7122002B2 (ja) 2017-03-01 2022-08-19 国立大学法人北海道大学 疾患モデル非ヒト動物の製造方法、疾患モデル非ヒト動物、該動物を用いた薬剤のスクリーニング方法及び疾患リスク判定方法
AU2018248672B2 (en) * 2017-04-05 2021-09-30 Korea Research Institute Of Bioscience And Biotechnology NK cell-activating fusion protein, NK cell, and pharmaceutical composition including same
EP3618868A4 (en) 2017-05-05 2021-02-24 Allakos Inc. METHODS AND COMPOSITIONS FOR TREATING ALLERGIC EYE DISEASES
WO2019037067A1 (zh) * 2017-08-25 2019-02-28 法玛科技顾问股份有限公司 巨噬细胞发炎蛋白-1β(MIP-1β)抑制剂用以治疗及控管动脉粥状硬化的用途
JP7543135B2 (ja) * 2017-10-13 2024-09-02 エー アンド ジー ファーマシューティカル，インコーポレイテッド プロスタグランジンｆ２受容体阻害剤に対するモノクローナル抗体及びコンジュゲート、並びにそれらの使用
EP3732196A4 (en) * 2017-12-28 2022-01-05 Astute Medical, Inc. ANTIBODIES AND DOSAGES FOR CCL14
US20200408777A1 (en) * 2018-02-26 2020-12-31 Cornell University Quantitative biomarkers of ehv-1 susceptibility and protection
JP7407742B2 (ja) * 2018-05-11 2024-01-04 ハルシオン セラピューティクス インコーポレイテッド Ｇａｓｐ－１顆粒を標的とする結合性タンパク質及びキメラ抗原受容体ｔ細胞並びにそれらの使用
KR20210095165A (ko) 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
CN110117329B (zh) * 2019-04-03 2020-12-08 河北浓孚雨生物科技有限公司 包含趋化因子与结合伴侣的融合多肽及其用途
WO2021003284A1 (en) * 2019-07-02 2021-01-07 Astute Medical, Inc Antibodies and assays for ccl14
KR102489282B1 (ko) * 2019-07-02 2023-01-17 고려대학교 산학협력단 Ccl4, ccl5, ccl20, 및 ccl21을 유효성분으로 포함하는 임신촉진용 조성물
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置
CN113893331A (zh) * 2020-07-06 2022-01-07 中国农业科学院特产研究所 一种诱导母鹿生茸的产品及其制备方法和诱导母鹿生茸的方法和应用
WO2022011110A2 (en) * 2020-07-08 2022-01-13 Georgia Tech Research Corporation Compositions and methods for the diagnosis and treatment of sars-cov-2 virus infection
IL302078A (en) 2020-10-16 2023-06-01 Lanova Medicines Ltd Anti-CCR8 monoclonal antibodies and their uses
CN115598111A (zh) * 2021-07-08 2023-01-13 南京大学（Cn） 基于邻位诱导免疫分析的特异性杂交瘤细胞化学发光筛选方法
CN114990073A (zh) * 2022-05-27 2022-09-02 河南农业大学 一种抗猪ccl2蛋白的单克隆抗体及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CA2140638C (en) 1992-07-24 2010-05-04 Raju Kucherlapati Generation of xenogeneic antibodies
US7018627B1 (en) 1995-06-07 2006-03-28 Icos Corporation Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof
US6498015B1 (en) * 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
US6316420B1 (en) 1998-07-28 2001-11-13 Technion Research And Development Foundation Ltd. DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis
US6420346B1 (en) * 2000-02-07 2002-07-16 Rappaport Family Institute For Research In The Medical Sciences Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis
CA2496419A1 (en) 2002-08-19 2004-02-26 Abgenix, Inc. Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
WO2004050836A2 (en) * 2002-11-27 2004-06-17 Biogen Idec Ma Inc. Humanized antibodies against monocyte chemotactic proteins
DE602005013572D1 (de) 2004-12-21 2009-05-07 Serono Lab Cc-chemokin-antagonisten
MX2010001307A (es) 2007-08-02 2010-07-30 Novimmune Sa Anticuerpos anti-proteína regulada con la activación, expresada y secretada por los linfocitos t normales y metodos de uso de los mismos.
ES2531561T3 (es) * 2009-08-28 2015-03-17 Regeneron Pharmaceuticals, Inc. Anticuerpos de antiquina que se enlazan a múltiples quimioquinas CC

Also Published As

Publication number Publication date
DK2470671T3 (en) 2015-02-09
WO2011025962A1 (en) 2011-03-03
AU2010286516A2 (en) 2012-06-14
MX2012002427A (es) 2012-08-03
SMT201500011B (it) 2015-03-05
US20130108640A1 (en) 2013-05-02
SI2470671T1 (sl) 2015-04-30
CA2771781C (en) 2019-01-15
JP6109571B2 (ja) 2017-04-05
CN102782148A (zh) 2012-11-14
KR101778813B1 (ko) 2017-09-14
PT2470671E (pt) 2015-02-05
CA2771781A1 (en) 2011-03-03
US20110059107A1 (en) 2011-03-10
IN2012DN01769A (pl) 2015-06-05
EP2470671B1 (en) 2014-12-24
AU2010286516B2 (en) 2016-10-06
CN102782148B (zh) 2016-04-20
EP2470671A1 (en) 2012-07-04
KR20120091013A (ko) 2012-08-17
US9005617B2 (en) 2015-04-14
JP2016135783A (ja) 2016-07-28
US8313747B2 (en) 2012-11-20
RU2012111820A (ru) 2013-10-10
AU2010286516A1 (en) 2012-03-08
EP2470671A4 (en) 2013-04-03
BR112012004387A2 (pt) 2015-09-08
US20150166647A1 (en) 2015-06-18
ES2531561T3 (es) 2015-03-17
HRP20150162T1 (hr) 2015-05-08
JP2013503192A (ja) 2013-01-31

Similar Documents

Publication Publication Date Title
PT2470671E (pt) Anticorpos anticinas que se ligam a múltiplas quimiocinas
HRP20190047T1 (hr) Protutijela koja se vežu na csf1r
HK1217711A1 (zh) 特異於鈣粘素- 的抗體
IL214996A0 (en) Anti-bcma antibodies
GB0920127D0 (en) Antibodies
ZA201202329B (en) Antibodies that specifically bind to the epha2 receptor
ZA201104545B (en) Anti-siglec-15 antibody
GB0909906D0 (en) Antibodies
EP2427496A4 (en) ANTI-VEGF-D ANTIBODIES
GB0920324D0 (en) Antibodies
GB2473934B (en) Anti-VEEV antibody
EP2499256A4 (en) ANTI-C-MPL ANTIBODIES
EP2424892A4 (en) DC-STAMP ANTIBODY
EP2524964A4 (en) FOR THE ACTIVATED EGFR SPECIFIC ANTIBODY
GB0911712D0 (en) Antibody
GB0908945D0 (en) Antibodies